These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 10634350)

  • 1. The functional anatomy, neurochemistry, and pharmacology of anxiety.
    Ninan PT
    J Clin Psychiatry; 1999; 60 Suppl 22():12-7. PubMed ID: 10634350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative review of SNRIs in anxiety.
    Silverstone PH
    J Clin Psychiatry; 2004; 65 Suppl 17():19-28. PubMed ID: 15600378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generalized anxiety disorder: raising the expectations of treatment.
    Allgulander C; Sheehan DV
    Psychopharmacol Bull; 2002; 36 Suppl 2():68-78. PubMed ID: 17450651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
    Judge R; Wagner BE
    J Clin Psychiatry; 1999 Nov; 60(11):795-6. PubMed ID: 10584775
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
    Meoni P; Salinas E; Brault Y; Hackett D
    J Clin Psychiatry; 2001 Nov; 62(11):888-93. PubMed ID: 11775049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine in the treatment of anxiety disorders.
    Katzman M
    Expert Rev Neurother; 2004 May; 4(3):371-81. PubMed ID: 15853535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in the neurobiological basis of anxiety disorders.
    Gorman JM; Hirschfeld RM; Ninan PT
    Psychopharmacol Bull; 2002; 36 Suppl 2():49-67. PubMed ID: 12490823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generalized anxiety disorder in family practice patients.
    Magill MK; Gunning K
    Am Fam Physician; 2000 Oct; 62(7):1497, 1501-2, 1504. PubMed ID: 11037071
    [No Abstract]   [Full Text] [Related]  

  • 10. Synergistic benefits of serotonin and noradrenaline reuptake inhibition.
    Nelson JC
    Depress Anxiety; 1998; 7 Suppl 1():5-6. PubMed ID: 9597344
    [No Abstract]   [Full Text] [Related]  

  • 11. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder.
    Ballenger JC
    J Clin Psychiatry; 2001; 62 Suppl 19():11-9. PubMed ID: 11577786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of antidepressants currently used to treat anxiety disorders.
    Feighner JP
    J Clin Psychiatry; 1999; 60 Suppl 22():18-22. PubMed ID: 10634351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder.
    Strawn JR; Wehry AM; DelBello MP; Rynn MA; Strakowski S
    Depress Anxiety; 2012 Apr; 29(4):328-39. PubMed ID: 22511364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of generalized anxiety disorder.
    Gorman JM
    J Clin Psychiatry; 2002; 63 Suppl 8():17-23. PubMed ID: 12044104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder.
    Whalen PJ; Johnstone T; Somerville LH; Nitschke JB; Polis S; Alexander AL; Davidson RJ; Kalin NH
    Biol Psychiatry; 2008 May; 63(9):858-63. PubMed ID: 17964548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR; DuPont RL; Hedges D; Haskins JT
    J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder.
    Kelsey JE
    Depress Anxiety; 2000; 12 Suppl 1():81-4. PubMed ID: 11098419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
    Feighner JP; Entsuah AR; McPherson MK
    J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mergers and acquisitions among psychotropics: antidepressant takeover of anxiety may now be complete.
    Stahl SM
    J Clin Psychiatry; 1999 May; 60(5):282-3. PubMed ID: 10362433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.